Changes to cholesterol treatment guidelines expand statin eligibility
An estimated 21.5 million additional adults in the United States may now be eligible for statins under updated cholesterol treatment guidelines, according to a new study, reports BritPanorama.
The analysis, published on July 20 in the journal JAMA, aimed to evaluate the implications of the 2026 blood cholesterol guidelines issued by the American Heart Association, the American College of Cardiology, and nine collaborating medical societies, comparing them with the previous 2018 guidelines. The assessment found that the total number of Americans eligible for statins—medications that lower cholesterol—could rise to approximately 87.5 million people, representing more than half of adults aged 30 to 79.
This significant change raises questions about what prompted the expansion and whether being deemed eligible for statins necessitates immediate medication initiation. Dr. Leana Wen, an emergency physician and clinical associate professor at George Washington University, provided insight. According to Wen, the study analyzed data from over 4,300 participants in a national health survey collected between 2017 and 2023, designed to represent around 154 million American adults aged 30 to 79 without known cardiovascular disease.
Under the new guidelines, four major changes account for the considerable increase in eligibility for statin therapy. Firstly, the age range for assessing cardiovascular risk has expanded; the previous guidelines focused primarily on adults aged 40 to 75, while the new recommendations include adults aged 30 to 79. Secondly, the thresholds used to categorize cardiovascular risk have been lowered, with individuals now classified as high risk if they have a 10% chance of experiencing a cardiovascular event within the next decade, intermediate risk at a 5% chance, and borderline risk at 3%.
Furthermore, the guidelines now take into greater account specific medical conditions, allowing individuals aged 40 to 75 with advanced chronic kidney disease or HIV to potentially qualify for statin therapy. Lastly, the updated guidelines emphasize long-term cardiovascular risk, suggesting that someone with less than a 3% chance of developing cardiovascular disease over the next 10 years could still be considered for a statin if their estimated 30-year risk is at least 10%.
While many of the newly eligible adults have low estimated risk over the next decade, Wen explained that cardiovascular disease develops gradually, with low-density lipoprotein (LDL), or “bad” cholesterol, gradually building up within artery walls and heightening the risk of heart attacks and strokes. The revised guidelines intend to identify individuals who may benefit from preventative measures, such as statin therapy, earlier rather than delaying until significant risk manifests.
It is crucial to note that being eligible does not entail an obligation to commence statin treatment. According to Wen, individuals at high risk should consider statin therapy based on their specific health conditions. For others, the decision ought to be individualized, factoring in elements like age, smoking status, family history, and other medical conditions.
Individuals interested in determining their eligibility should engage in discussions with their healthcare providers to assess their cholesterol levels and overall health, potentially utilizing tools like the American Heart Association’s PREVENT calculator to evaluate their cardiovascular disease risk over the next decade—and for younger adults, over 30 years.
As dietary and lifestyle factors play essential roles in managing cardiovascular health, the guidelines emphasize that heart-healthy strategies—such as maintaining a balanced diet and engaging in regular physical activity—are integral alongside any medical treatment.
The goal of these guidelines thus encapsulates an approach to initiate cholesterol management earlier and tailor it more closely to individual risk profiles, advocating for comprehensive conversations between patients and their healthcare providers regarding prevention strategies well before any cardiovascular issues may arise.
